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REVIEW
Use of viscoelastic substance in ophthalmic 
surgery – focus on sodium hyaluronate
Abstract: Among viscoelastic substances, sodium hyaluronate has become the most popular for 
intraocular surgeries since the introduction of Healon® (sodium hyaluronate 1%, 4 × 106 daltons) in 
1979. This review focuses on the recent development of a new generation of sodium hyaluronate 
agents with new rheologic properties and the relevant new techniques used in cataract, glaucoma, 
corneal, and vitreoretinal surgeries. The introduction of sodium hyaluronate agents with different 
rheologic properties has improved the safety and reliability of intraocular surgeries. Although there 
have been numerous studies reporting the effectiveness of viscoelastic substances in intraocular 
surgeries, rigorous validation by multi-center randomized control trials is lacking in many cases. 
At present, no single viscoelastic agent is most suitable to all of the various intraocular surgical 
techniques. Therefore, ophthalmologic surgeons should keep up with recent developments of 
viscoelastic agents and relevant surgical techniques for better patient care.
Keywords: sodium hyaluronate, cataract surgery, glaucoma surgery, corneal transplantation, 
vitreoretinal surgery
Sodium hyaluronate (hyaluronic acid or hyaluronan) is a naturally occurring, high-
molecular-mass, polysaccharide present in the extracellular matrix of connective 
tissues. It is also found in the aqueous humor and the vitreous and coats the corneal 
endothelium (Balazs 1983). Sodium hyaluronate, and other viscoelastic substances 
including methylcellulose, chondroitin sulfate, polyacrylamide, and collagen, have 
been used in intraocular surgery since the 1970s (Liesegang 1990).
Since the introduction of Healon® (sodium hyaluronate 1%, 4 × 106 daltons) in 1979 
(Balazs et al 1979), sodium hyaluronate has become the most popular and indispensable 
viscoelastic substance for use in intraocular surgery. Comprehensive reviews published 
since then have described pharmacological, physiological, and clinical aspects of 
sodium hyaluronate in ophthalmologic applications in detail (Liesegang 1990; Goa and 
Benﬁ  eld 1994). Along with the advent of a new generation of sodium hyaluronates, 
these compounds rapidly became essential tools for integral parts of intraocular surgery; 
and the term ophthalmic viscosurgical devices (OVDs) for viscoelastic substances was 
introduced in the beginning of this century. This review focuses on recent developments 
in the application of sodium hyaluronates to various intraocular surgeries.
Sodium hyaluronate in the early 1990s
In the early 1990s, sodium hyaluronate agents could be classiﬁ  ed as cohesive 
(eg, Healon®; HealonGV®, sodium hyaluronate 1.4%, 5 × 106 daltons) or dispersive 
(eg, Viscoat®, sodium hyaluronate 3%, 5 × 105 daltons – chondroitin sulfate 4%). 
Cohesiveness, which means the degree to which a material adheres to itself, is a function 
of molecular weight and elasticity and is proportional to the viscosity (a measure of its 
resistance to ﬂ  ow) at zero shear rate (Liesegang 1990). The viscosity is a function of 
the molecular weight, concentration, and temperature. The plot of dynamic viscosity 
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against shear rate (lower viscosity at higher shear rate) 
reveals the pseudoplasticity of sodium hyaluronate. High 
pseudoplasticity facilitates injection of sodium hyaluronate 
through a small-gauge cannula. Elasticity is the tendency of 
a material to return to its original shape after being stretched 
or compressed. Long-chain molecules tend to be more elastic 
than short-chain molecules.
Cohesive agents have long molecular chains (high 
molecular weight) and are strongly entangled, whereas 
dispersive agents have low molecular weight and short 
molecular chains. Maintenance of anterior chamber depth 
and easy removal by aspiration are desirable consequences 
of cohesiveness, whereas coating the corneal endothelium 
is best done with dispersive materials.
New generation of sodium 
hyaluronate agents
Healon®5
In 1998, a new sodium hyaluronate agent, Healon®5 (sodium 
hyaluronate 2.3%, 4 × 106 daltons), was introduced. Because 
of its higher concentration, Healon®5 has even higher 
viscosity at rest (7 × 106 mPas) than superviscous cohesive 
HealonGV® (2 × 106 mPas). Healon®5 behaves like the 
superviscous cohesives at low shear rate, but its distinguishing 
property, which is solid-like behavior due to its rigid 
molecular structure, appears at high shear rate. The biphasic 
behavior of Healon®5 created a new class of OVDs termed 
viscoadaptive (Arshinoff 1999A). Healon®5 is also called 
pseudodispersive because fracturing that occurs due to its 
high rigidity before being sucked into the irrigation/aspiration 
port makes its complete removal more difﬁ  cult than removal 
of cohesive OVDs. In contrast, dispersive OVDs such as 
Viscoat® are resistant to aspiration because lack of sufﬁ  cient 
cohesion allows only small pieces to be aspirated at a time 
(Arshinoff and Wong 2003). A randomized prospective study 
showed that Healon®5 caused an intraocular pressure (IOP) 
increase 4 hours postoperatively that was not signiﬁ  cantly 
different from that caused by OcuCoat® and Celoftal® 
(hydroxypropyl methylcellulose 2.0%), Viscoat®, and 
HealonGV®, and it also resulted in the lowest mean corneal 
endothelial cell loss (Holzer 2001). In another randomized 
multicenter clinical trial comparing Healon®5 and Healon®, 
Healon®5 was rated better than Healon® in retention during 
phacoemulsification, in anterior chamber maintenance 
during continuous curvilinear capsulorhexis (CCC), and in 
facilitation of intraocular lens (IOL) implantation, whereas it 
was more difﬁ  cult to inject and remove than Healon® (Oshika 
et al 2004). Furthermore, studies using animal eyes found that 
Healon®5 was more resistant to removal than DisCoVisc®, 
a new class of OVD as described below (Bissen-Miyajima 
2006; Oshika et al 2006).
To overcome the problem of Healon®5 removal, two 
removal techniques are commonly used. One is the rock’n 
roll technique in which the irrigation/aspiration handpiece 
is moved in a circular fashion in the anterior chamber at 
the iris plane using gentle pressure with the handpiece on 
the edge of the IOL optic (Arshinoff 1997). The other is a 
two-compartment (behind-the-lens) technique in which the 
irrigation/aspiration tip is ﬁ  rst placed behind the IOL optic 
to remove the OVD in the capsular bag while the anterior 
chamber is still ﬁ  lled with the OVD, and then it is moved 
into the anterior chamber to remove the remaining OVD there 
(Tetz and Holzer 2000). In a prospective randomized study 
of 159 patients comparing the two removal techniques, the 
two-compartment technique had a signiﬁ  cantly shorter mean 
Healon®5-removal time and a lower mean IOP 5 hours after 
surgery than did the rock’n roll technique, suggesting that 
the two-compartment technique is more effective than the 
rock’n roll technique (Zetterström et al 2002).
However, for surgeons who do not like to place the 
irrigation/aspiration tip behind the IOL, Cionni et al (2004) 
described the empty-bag technique for injecting an acrylic 
foldable IOL through an injector using Healon®5. In this 
technique, Healon®5 is placed in the anterior chamber 
and then the capsular bag is expanded with balanced salt 
solution before IOL implantation. The authors concluded 
that the technique can often eliminate the need to place the 
irrigation/aspiration tip behind the IOL optic to remove 
Healon®5 completely. A similar technique was also reported 
by Arshinoff (2002) as an application of the ultimate soft-
shell technique described below.
IOL material is reported to have a signiﬁ  cant effect on 
the removal time of Healon®5 (Auffarth et al 2004A).The 
hydrophobic acrylic IOL allows adhesion of Healon®5 more 
than PMMA or silicone IOLs and, therefore, has the longest 
removal time.
DisCoVisc®
The quest for more ideal OVDs for cataract surgery 
yielded DisCoVisc® (sodium hyaluronate 1.6%,1.7 × 106 
daltons – chondroitin sulfate 4%), which belongs to another 
new class of OVD called viscous dispersives, in 2003. 
DisCoVisc® possesses a zero-shear viscosity similar to 
Healon®, but is dispersive like Viscoat® (Arshinoff and Jafari 
2005). DisCoVisc® belongs to the viscous cohesives according Clinical Ophthalmology 2008:2(1) 23
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to the OVD classiﬁ  cation due to its zero-shear viscosity, but 
its dispersive property does not ﬁ  t this classiﬁ  cation. Earlier 
OVDs had a cohesion property that correlated highly with 
zero-shear viscosity. The dissociation of viscosity and cohe-
sion in DisCoVisc® was discovered by measurement of OVD 
cohesion with the Poyer assay method (Poyer et al 1998). A 
new OVD classiﬁ  cation was deﬁ  ned using zero-shear viscosity 
and cohesion independently (Arshinoff and Jafari 2005).
The dispersive property of DisCoVisc® was conﬁ  rmed 
in several studies. OVD retention was measured between the 
corneal endothelium and the anterior chamber using in vivo 
confocal microscopy after simulated phacoemulsiﬁ  cation in 
rabbit eyes (Petroll et al 2005). The authors found that OVD 
retention of DisCoVisc® was comparable to Viscoat® and was 
signiﬁ  cantly greater than that of Provisc® (sodium hyaluronate 
1%, 1.9 × 106 daltons), Healon®, Healon®5, and Amvisc Plus® 
(sodium hyaluronate 1.6%, 1.5 × 106 daltons). The results 
suggest that DisCoVisc® may provide good corneal endothelial 
cell protection during phacoemulsiﬁ  cation that is comparable 
to Viscoat®. Bissen-Miyajima (2006) recorded the behavior 
of OVDs stained with ﬂ  uorescein during phacoemulsiﬁ  cation 
and IOL implantation surgery performed in porcine eyes, and 
found that DisCoVisc®, Viscoat®, and Healon®5 were not 
aspirated during phacoemulsiﬁ  cation and that removal time 
with the irrigation/aspiration tip was signiﬁ  cantly shorter with 
DisCoVisc® than with Viscoat® or Healon®5. Furthermore, 
using a similar experimental model, Oshika et al (2006) 
reported that DisCoVisc® was retained better in the anterior 
chamber and was easier to remove in comparison with Healon®5 
and concluded that DisCoVisc® is highly advantageous when 
performing cataract surgery with a single OVD.
VisThesia®
VisThesia® is composed of 2 products: VisThesia Topi-
cal (sodium hyaluronate 0.3%, lidocaine 2%), for corneal 
hydration and topical anesthesia, and VisThesia Intracameral 
(sodium hyaluronate 1.5% and lidocaine 1%), for high-
viscosity, cohesive OVD and intracameral anesthesia. Ran-
domized trials found that intracameral lidocaine 1% used as a 
supplement to topical anesthesia may slightly reduce patients 
discomfort and may not be toxic to the corneal endothelial cells 
when applied once prior to capsulorhexis (Carino et al 1998; 
Garcia et al 1998; Tseng and Chen 1998; Gillow et al 1999). As 
for VisThesia®, Poyales-Galan and Pirazzoli (2005) reported 
corneal endothelial cell loss comparable to that reported for 
similar OVDs, whereas Perone et al (2007) reported worse cor-
neal endothelial protection than with DuoVisc® (VIscoat® plus 
ProVisc®) suggesting lidocaine 1% may be toxic when used 
as an ingredient of OVDs. Removal properties of VisThesia® 
should be similar to those of sodium hyaluronate 1.5% because 
a mixture of lidocaine 1.0% with sodium hyaluronate 1.5% 
does not signiﬁ  cantly alter its removal time from the capsular 
bag of postmortem human eyes (Pandey 2003).
Cataract surgery
The main purpose for using sodium hyaluronate in cataract 
surgery is to maintain a stable anterior chamber depth and 
protect the corneal endothelial cells from being damaged 
during the entire surgical procedure. The advent of sodium 
hyaluronate with different rheologic properties has promoted 
the development of techniques in cataract surgery that 
decrease surgical complications and make challenging cases 
easier. However, postoperative elevation of IOP as an adverse 
effect of using sodium hyaluronate still remains a matter of 
concern for most surgeons.
Soft-shell technique
The technique (Arshinoff 1999B) using dispersive and 
cohesive OVDs creates a smooth, ﬂ  at layer of dispersive 
OVD (Viscoat®) adjacent to the corneal endothelium over 
a high-viscosity, cohesive OVD such as Healon®. This 
technique is effective in reducing corneal endothelial cell 
loss after phacoemulsiﬁ  cation surgery, especially in eyes 
with dense nuclear opacity, when compared with results 
using a single cohesive or dispersive OVD only (Miyata 
et al 2002; Kim and Joo 2004). A Medline search did not 
ﬁ  nd any articles that compared the soft shell technique with 
DiscoVisc®, a new viscous dispersive OVD. However, 
according to in vitro studies (Bissen-Miyajima 2006; Oshika 
et al 2006), removal will be better with DiscoVisc® than 
with the soft shell technique because DiscoVisc® requires 
a shorter aspiration time by an irrigation/aspiration tip than 
Viscoat®. As for endothelial cell protection by DiscoVisc®, 
it may be similar to that of the soft shell technique because 
residual OVD thickness of DiscoVisc® following simulated 
phacoemulsiﬁ  cation was similar to that of Viscoat® (Petroll 
et al 2005). Clinical studies are needed to determine whether 
a single OVD, DiscoVisc®, can replace the soft shell 
technique which requires two OVDs.
Arshinoff (2002) has developed a new technique called the 
ultimate soft-shell technique. This technique compartmentalizes 
the anterior chamber using the ultimate low-viscosity ﬂ  uid 
(balanced salt solution or trypan blue) underneath viscoadaptive 
OVDs (Healon5® or I-Visc Phaco®, sodium hyaluronate 2.5%) 
with which the anterior chamber is ﬁ  lled to the desired extent 
(for capsulorhexis, 60%–80%; for capsular staining, 90%; for Clinical Ophthalmology 2008:2(1) 24
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IOL implantation, 60%). The technique reduces the resistance 
to advancing the capsulorhexis with a needle or forceps while 
maintaining tamponade to the lens surface well, and also 
reduces the amount of dye required for capsular staining of 
mature or white cataracts. Furthermore, this technique can be 
applied to the IOL implantation followed by an easy aspiration 
of OVDs in a way similar to the empty-bag technique described 
by Cionni et al (2004).
Intraoperative ﬂ  oppy iris syndrome (IFIS)
Chang and Campbell (2005) reported a new small-pupil 
syndrome associated with tamsulosin, a systemic α-1 blocker 
used to treat benign prostatic hypertrophy. The clinical intraop-
erative triad of the syndrome consists of ﬂ  uttering and billowing 
of the iris stroma caused by ordinary intraocular ﬂ  uid currents, 
a propensity for iris prolapse through the phacoemulsiﬁ  cation 
and/or side-port incisions, and progressive constriction of the 
pupil during surgery. In a prospective study of 900 consecutive 
cataract surgeries, they found the prevalence of IFIS to be 
2.2%, and 94% of the IFIS cases had a history of taking 
systemic tamsulosin. In order to complete cataract surgery 
safely in eyes with IFIS syndrome, Healon®5 may help to 
mechanically expand the pupil (viscomydriasis) and prevent 
the iris from prolapsing by adding tone to the iris (Chang and 
Campbell 2005). Furthermore, Arshinoff (2006) described 
detailed methods to deal with eyes with IFIS syndrome that 
involve injecting Viscoat®, Healon®5, and balanced salt solution 
consecutively into the anterior chamber (modiﬁ  ed soft-shell 
technique - ultimate soft-shell technique).
Capsulorhexis in pediatric
cataract surgery
Since the introduction by Gimbell and Neuhann (1990), 
CCC has become a standard technique in cataract surgery. 
However, there are challenging cases in which it is difﬁ  cult 
to complete CCC. Among them, pediatric cataract is one 
of the most difﬁ  cult categories because the pediatric lens 
capsule is more elastic than the adult lens capsule and the 
posterior pressure which pushs up the lens is higher in 
pediatric eyes than in adult eyes. By using Healon®5, Jeng 
et al (2004) successfully performed CCC in 9 of 10 eyes 
(6.4 ± 1.4 years), but they completed only 7 of 15 eyes with 
Healon® or Viscoat® (7.6 ± 1.4 years). Furthermore, even 
in much younger cases (median age of surgery = 9 months; 
range, 1–54 months), Gibbon and Quinn (2006) reported that 
CCC was successfully completed with Healon®5 in 21 of 22 
eyes. They tried and failed CCC with Healon GV® in 2 eyes, 
and postulated that the super-viscous cohesive property of 
Healon®5 made CCC completion possible in pediatric eyes 
by stabilizing the anterior chamber depth better.
Use of sodium hyaluronate in cases
of posterior capsule rupture
Sodium hyaluronate is sometimes helpful to tamponade a 
posterior capsule rupture for subsequent IOL implantation. 
However, Shihota et al (2003) reported 4 cases with 
intractable glaucoma after complicated phacoemulsiﬁ  caiton 
during which Healon® was used to tamponade a central 
posterior capsule rupture. Incomplete removal of Healon® 
in the vitreous cavity was considered to be a primary reason 
for severe IOP elevation, and the authors recommended early 
removal of OVDs by pars plana vitrectomy in the presence 
of ultrasonographic evidence of intravitreal OVDs.
Chang and Packard (2003) reported the usefulness of 
Viscoat® for retrieval of a partially descended nucleus after 
posterior capsule rupture. They injected Viscoat® through a 
pars plana incision to elevate the nuclear pieces into the anterior 
chamber. They selected Viscoat® for this technique because its 
dispersive property makes it less likely to cause a protracted 
IOP rise in case of incomplete removal and it may block further 
vitreous prolapse more effectively than other high-molecular 
weight cohesive OVDs. Actually, they experienced no early 
postoperative IOP elevation in 8 consecutive patients.
Anterior lens capsule staining with dyes
Indocyanine green (Horiguchi et al 1998) and trypan blue 
(Melles et al 1999B) are widely used for better visualization 
of the anterior lens capsule during CCC in difﬁ  cult cases such 
as white or brunescent cataracts. In order to prevent dyes from 
staining other intraocular structures excessively, OVDs are used 
concomitantly, but controlling the staining area is sometimes 
difﬁ  cult. In this regard, Arshinoff (2002) reported the usefulness 
of the ultimate soft-shell technique for capsular staining as 
described above. Marques et al (2004) reported a similar 3-step 
technique that prevents uncontrolled dispersion and excessive 
accumulation of dye within an OVD. They injected Healon®5 
to ﬁ  ll the anterior chamber, then injected balanced salt solution 
gently onto the anterior lens capsule, and ﬁ  nally injected the dye 
slowly through a specially-designed 27-gauge cannula.
Postoperative complications
and OVDs
IOP elevation by OVDs
A number of studies have shown that all viscoelastic substances 
are capable of increasing IOP in the early postoperative 
period (Liesegang 1990; Goa and Benﬁ  eld 1994). The IOP Clinical Ophthalmology 2008:2(1) 25
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elevation by viscoelastic substances is caused by a reduction of 
aqueous outﬂ  ow due to blockage of the trabecular meshwork 
where the ﬂ  uids exit the eye. Therefore, complete removal 
of OVDs is recommended after IOL implantation. The 
IOP elevation is usually transient, peaking at 4 to 7 hours 
postoperatively and returning to baseline within several days, 
but the maximum IOP may exceed 30 mmHg. Therefore, 
careful monitoring of IOP and IOP-lowering therapy may 
be necessary, especially in patients with glaucoma who have 
a compromised outﬂ  ow facility. Molecular characteristic of 
OVDs should have signiﬁ  cant effects on the likelihood of IOP 
elevation. Torngren et al (2000) found positive correlations 
between concentration and maximum IOP increase and 
between molecular weight and time to peak in rabbit eyes 
after aqueous exchange with OVDs. However, no consensus 
has been reached among clinical studies as to which OVD 
causes most or least elevation of IOP postoperatively in 
cataract surgery. The lack of consensus is due partly to the 
variability of patient characteristics (Arshinoff et al 2002), the 
amount of OVDs remaining in the eye at the end of surgery, 
and the timing of IOP measurements (Rainer et al 2005). 
For example, Viscoat®, an OVD with low-molecular weight 
and short chain, is supposed to pass through the trabecular 
meshwork easily and be less likely to cause IOP elevation, 
whereas it is most resistant to complete removal due to its 
dispersive property. Rainer et al (2005) reported signiﬁ  cant 
IOP increases during the ﬁ  rst 24 hours, peaking at 1 hour 
after surgery (13.4 ± 9.4 mm Hg), in eyes that were operated 
with Viscoat®. As for Healon 5®, randomized studies found 
that the postoperative IOP in Healon 5®-treated eyes was 
less than that in Viscoat®-treated eyes at 6 hours, but was 
not signiﬁ  cantly different from Viscoat®-treated eyes at 1 
day (Rainer et al 2000). Other studies found no difference 
in early postoperative IOP between Healon 5®-treated and 
other OVD-treated eyes (OcuCoat®, Celoftal®, Viscoat® and 
Healon GV®, Holzer et al 2001; Healon GV®, Arshinoff et al 
2002; Healon®, Oshika et al 2004; Amvisc Plus®, Moser et al 
2004). No randomized studies examining the postoperative 
IOP increase in DisCoVisc® – or Visthesia®-treated eyes have 
been reported.
A ﬂ  uorescently-labeled OVD enabled better visualization, 
facilitated complete removal, and caused a signiﬁ  cantly 
smaller IOP increase than a clear OVD (Smith and Burt 
1992). Although this technique has not become a routine 
procedure yet, it has been used in experimental studies with 
ex vivo eyes to examine retention or removal of OVDs during 
cataract surgery (Auffarth et al 2004A; Auffarth et al 2004B; 
Bissen-Miyajima 2006; Oshika et al 2006).
Mechanism of corneal endothelial
cell loss during cataract surgery
and the protection by OVDs
During cataract surgery, mechanical damage from surgical 
instruments or lens fragments may cause corneal endothelial 
cell loss, and OVDs have been used for protection since the 
era of extracapsular cataract extraction began. In addition, 
ultrasound phacoemulsiﬁ  cation causes formation of highly 
reactive free radicals that are generated by the heat from 
cavity-implosion of decomposed water (Shimmura et al 1992; 
Holst et al 1993). The free radicals induce oxidative tissue 
damage including corneal endothelial cell loss. In this regard, 
OVDs could reduce the amount of free radicals produced 
by phacoemulsiﬁ  cation in experimental studies (Shimmura 
et al 1992; Holst et al 1993; Takahashi et al 2002; Camillieri 
et al 2004; Takahashi et al 2006) and also in a clinical study 
(Augustin and Dick 2004). Takahashi et al (2006) showed 
that an OVD’s inhibitory effect against free radical formation 
in the phacoemulsiﬁ  cation simulations with an eye model 
was compatible with its retention properties in the anterior 
chamber under different irrigation/aspiration settings, and 
that Viscoat®, with a high irrigation/aspiration setting, was 
superior to Healon®, Opegan® (sodium hyaluronate 1%, 
0.6–1.2 × 106 daltons) and Healon®5 in suppression of free 
radical formation.
The heat generation by phacoemulsification, which 
contributes not only to the corneal endothelial cell loss 
but also to wound burn and breakdown of the blood-
aqueous barrier, was considered by Jurowski et al (2006) 
by measuring the increase in corneal surface temperature 
of rabbit eyes during phacoemulsiﬁ  cation. They suggested 
that dispersive OVDs may be more effective in preventing 
thermal injury.
Glaucoma surgery
To improve surgical outcome and reduce intraoperative and 
postoperative complications, sodium hyaluronate has been 
used for glaucoma surgeries including trabeculectomy and 
goniotomy. Furthermore, Stegmann et al (1999) established 
a new non-penetrating glaucoma surgery, viscocanalostomy, 
using Healon GV®.
Trabeculectomy – intraoperative
use of sodium hyaluronate
Prior to the era of routine use of the antimetabolites 
mitomycin C (Kitazawa et al 1991) and 5-fluorouracil 
(Heuer et al 1984), excess filtration immediately after Clinical Ophthalmology 2008:2(1) 26
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trabeculectomy was considered to be necessary for long-term 
surgical success, especially in difﬁ  cult cases, but was likely 
to cause complications such as a flat anterior chamber 
and hypotony. To solve this problem, a number of studies 
evaluated the effectiveness of viscous and non-inﬂ  ammatory 
sodium hyaluronate in reducing early postoperative 
complications. In studies with a prospective and randomized 
design, intracameral or subconjunctival injection of sodium 
hyaluronate resulted in less frequent hypotony or ﬂ  attening 
of the anterior chamber (Alpar 1986; Charteris et al 1991; 
Barak et al 1992; Gulkilik et al 2006), although negative 
results were also reported (Hung 1985; Teekhasaenee and 
Ritch 1986; Raitta et al 1994; Lopes et al 2006).
The inconsistency of the results may stem from the 
variability of surgical techniques, especially the site and the 
time that the sodium hyaluronate remained in the eye. As 
pointed out by Fiore et al (1989), a postoperative shallow 
anterior chamber may cause corneal endothelial cell loss. 
The intracameral injection of sodium hyaluronate prior to 
trabeculectomy, which was randomly assigned, signiﬁ  cantly 
reduced corneal endothelial cell loss without the use of 
antimetabolites and intraoperative aspiration of sodium 
hyaluronate (Barak et al 1992) or with adjunctive mitomycin 
C and intraoperative removal of sodium hyaluronate (Shin 
et al 2003). Wilson and Lloyd (1986) found a lower incidence 
of postoperative hyphema in eyes treated with intracameral 
sodium hyaluronate and attributed the effect to possible 
microvascular clotting and a mechanical force by sodium 
hyaluronate, whereas Raitta et al (1994) reported opposite 
results. As for bleb morphology, subconjunctival injection 
of Healon®5 at the conclusion of trabeculectomy with 
adjunctive antimetabolites (mostly mitomycin C) resulted in 
more diffuse ﬁ  ltering blebs 1 year postoperatively, although 
the surgical success rate was not different from control eyes 
(Lopes et al 2006). Subconjunctival injection of Healon®5 
was also effective in treating a small conjunctival break 
that was created during trabeculectomy with adjunctive 
mitomycin C and was technically difficult to close by 
suturing without compromising ﬁ  ltration (Higashide et al 
2005). The site of the leakage was successfully plugged in 
3 consecutive cases by Healon®5 without suturing due to 
its superviscous cohesive properties at low shear rate. No 
leakage from the mildly elevated bleb was observed on the 
ﬁ  rst postoperative day and the technique was associated 
with no postoperative complications.
One possible drawback of the intraoperative injection 
of sodium hyaluronate during trabeculectomy is the early 
postoperative IOP rise which is especially dangerous to eyes 
with advanced visual ﬁ  eld loss (Liebmann et al 1990; Barak 
et al 1992). Close monitoring of the postoperative IOP is 
necessary, even though the removal of sodium hyaluronate 
from the anterior chamber at the conclusion of the surgery 
may decrease the risk of an IOP rise (Shin et al 2003).
Trabeculectomy – postoperative
use of sodium hyaluronate
Intracameral injection of sodium hyaluronate is reported 
to be useful to treat a postoperative shallow or ﬂ  at anterior 
chamber (Gerber and Cantor 1990; Juzych et al 1992; Osher 
et al 1996; Salvo et al 1999). A survey reported in 1999 
revealed that 75% of American Glaucoma Society members 
used sodium hyaluronate (most commonly Healon®) for 
anterior chamber reformation (Salvo et al 1999). However, 
the effect of sodium hyaluronate sometimes does not last 
long and repeated injection or alternative methods are 
then required. In expectation of a more prolonged stay 
and, therefore, better stabilization of the anterior chamber, 
Healon®5 was used for reformation of a flat anterior 
chamber with inconsistent success (Hoffman et al 2002; 
Geyer et al 2003; Gutierrez-Ortiz and Moreno-Lopez 2003). 
For cases in which Healon® or Healon®5 was ineffective, 
combined intracameral injection of sulfur hexaﬂ  uoride, a 
long-acting gas, and Healon® successfully stabilized the 
anterior chamber (Geyer et al 2003). A similar technique 
using perﬂ  uoropropane and an OVD was also reported 
(Kurtz and Leibovitch 2002). For postoperative hypotony, 
intracameral injection of Healon®5 raised IOP to an extent 
insufﬁ  cient to fully improve the hypotonus conditions 
(Altangerel et al 2006).
Goniotomy
The effectiveness of sodium hyaluronate in keeping sufﬁ  cient 
depth of the anterior chamber also facilitates goniotomy. 
Arnoult et al (1988) reported that sodium hyaluronate 
injected intracamerally during goniotomy prevented 
accidental loss of the anterior chamber, allowed maximal 
depth of the anterior chamber, diminished intraocular 
bleeding, and lowered the risk of injury to ocular tissues. 
In a retrospective study comparing goniotomy with and 
without Healon®, the authors concluded that the use of 
sodium hyaluronate may increase the success rate and 
decrease the complication rate by preventing hyphema and 
ﬂ  attening of the anterior chamber (Tamcelik and Ozkiris 
2004). Intracameral injection of sodium hyaluronate into 
the anterior chamber may also facilitate goniosynechialysis, 
another type of goniosurgery.Clinical Ophthalmology 2008:2(1) 27
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Viscocanalostomy
In 1999, Stegmann et al (1999) reported a new nonpenetrating 
glaucoma surgery, viscocanalostomy, using Healon GV® in 
order to avoid creating ﬁ  ltering blebs in eyes of black African 
patients with open-angle glaucoma who had a high risk of 
bleb infections. The authors hypothesized that the aqueous 
humor diffuses freely into a subscleral space through a 
window consisting of the Schlemm’s canal endothelium and 
Descemet’s membrane and enters into the Schlemm’s canal 
which was dilated by injecting a superviscous cohesive OVD 
(Healon GV®). The presence of OVD in the Schlemm’s canal 
was supposed to prevent ﬁ  brosis at the ostia adjacent to the 
subscleral space. It is not known whether the extent of the 
dilatation of Schlemm’s canal affects surgical success. In 
viscocanalostomy experiments with human eyes obtained at 
autopsy, the more viscous Healon®5 was superior to Healon 
GV® in dilating Schlemm’s canal 6.0 mm from the ﬂ  ap 
(Wild et al 2001). Experimental viscocanalostomy in rhesus 
monkey resulted in microperforation in the endothelial lining 
of Schlemm’s canal that was attributed to the increase in 
outﬂ  ow facility (Tamm et al 2004). The authors indicated 
that the persistence of endothelial defects in Schlemm’s 
canal 1 to 2 months after surgery may be caused by the 
inhibitory effects of sodium hyaluronate on thrombocyte 
aggregation.
In another application of sodium hyaluronate in non-
penetrating glaucoma surgery, SKGEL®, a reticulated 
hyaluronic acid implant, was developed for preserving 
the space under the scleral ﬂ  ap in non-penetrating deep 
sclerectomy (Sourdille et al 1999). In a study evaluating the 
effect of SKGEL® in non-penetrating deep sclerectomy, IOP 
control was better with SKGEL® than without it (Detry-Morel 
2001). SKGEL® was also applied in viscocanalostomy, but 
a prospective randomized trial in patients with open angle 
glaucoma failed to show better surgical outcome with 
SKGEL® when compared with standard viscocanalostomy 
(Luke et al 2003).
Corneal transplantation
Sodium hyaluronate is also indispensable to corneal 
transplantation surgery in several respects including 
protection of donor corneal endothelial cells (Frost et al 
2006). In a case with corneal perforation, trephination of the 
host cornea is difﬁ  cult due to hypotony. Healon®5 injected 
into the anterior chamber temporarily closed the corneal 
wound and facilitated the trephination (Rado and Berta 
2002). Healon®5 also facilitates deep lamellar keratoplasty 
in difﬁ  cult cases such as keratoconus that have a relatively 
high risk of rupturing Descemet’s membrane during 
surgery (Shimmura et al 2005). In the visco-dissection 
technique to separate Descemet’s membrane from posterior 
stroma (Melles et al 1999A; Melles et al 2000), Healon®5 
enabled precise control of visco-dissection and caused 
no Descemet’s membrane ruptures in 4 cases (Shimmura 
et al 2005).
Vitreoretinal surgery
Prior to its widespread use for IOL implantation, sodium 
hyaluronate was used as a substitute for the vitreous in 
retinal detachment surgery (Balazs et al 1972). Since then, 
there have been a number of reports of the usefulness of 
sodium hyaluronate in vitreoretinal surgery. Although 
sodium hyaluronate as an intraoperative tamponade in 
difﬁ  cult cases (Pruett et al 1979) has mostly been replaced 
by perﬂ  uorocarbon liquids (Chang 1987), viscodissection 
or viscodelamination using sodium hyaluronate is still an 
effective surgical technique in vitreoretinal surgery (McLeod 
and James 1988; Grigorian et al 2003).
Recent application of sodium hyaluronate in vitrectomy 
is for protection of the retina from chemical or mechanical 
damages. Staining with indocyanine green facilitates 
visualization and peeling of the internal limiting membrane 
in eyes with macular holes (Kadonosono et al 2000) 
and other vitreomacular interface abnormalities. The 
original preparation of indocyanine green for internal 
limiting membrane peeling was a mixture of the dye and 
a low molecular weight OVD (ﬁ  nal concentration, 0.06%; 
osmolarity, 270 mOsm) (Kadonosono et al 2000). Later, 
a number of clinical and experimental studies raised the 
possibility of toxicity of indocyanine green to the retinal 
pigment epithelium (Engelbrecht et al 2002; Ho et al 2003) 
and to retinal ganglion cells (Iriyama et al 2004; Yamashita 
et al 2006), and a reduction of the concentration and duration 
of dye exposure was recommended. In this regard, sodium 
hyaluronate 2.3% placed over the macular hole effectively 
prevented the subretinal migration of indocyanine green 
through the hole during vitrectomy for retinal detachment 
with a myopic macular hole (Cacciatori et al 2004). A 
similar technique was also reported for prevention of 
the contact between indocyanine green and the retinal 
pigment epithelium in a macular hole (Saito and Iida 2006). 
Regarding mechanical protection of the retina, Hanemoto 
et al (2004) reported that intravitreously injected Healon®5, 
which covered the posterior pole, prevented retinal damage 
during removal of a luxated crystalline lens by intravitreal 
phacoemulsiﬁ  cation.Clinical Ophthalmology 2008:2(1) 28
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Conclusions
Introduction of sodium hyaluronate agents with different 
rheologic properties and the new techniques that utilize 
these agents for cataract, glaucoma, corneal, and vitreoretinal 
surgeries has enabled us to perform intraocular surgeries 
more safely and reliably. Among the new generation of 
OVDs, Healon®5, a viscoadaptive OVD with the highest 
ability to stabilize the anterior chamber, not only facilitates 
CCC in difﬁ  cult cataract cases but also is useful in glaucoma 
and corneal surgeries. Healon®5 provides good corneal 
endothelial protection but its injection and removal are 
harder than that of cohesive OVDs. DisCoVisc®, a viscous 
dispersive OVD, may be an ideal OVD to perform cataract 
surgery with a single OVD because it remains well in the 
anterior chamber during phacoemulsiﬁ  cation and is more 
easily removed by an irrigation/aspiration tip than Viscoat® 
or Healon®5. Although there have been numerous studies 
reporting the effectiveness of viscoelastic substances in 
intraocular surgeries, many reports are subjective and 
based on results with a small number of cases. Accordingly, 
rigorous validation, ideally by multi-center randomized 
control trials, should help clarify the true effectiveness of 
OVDs in different kinds of intraocular surgeries. At present, 
no single OVD is most useful for all of the various intraocular 
surgical techniques. Therefore, ophthalmologic surgeons 
should keep up with recent developments of OVDs and 
relevant surgical techniques for better patient care.
Note
The authors of this manuscript have no proprietary or 
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